Skip to main content
SpringerLink
Log in

Nephrotoxicity of lomustine

A case report and literature review

  • Original Articles
  • Nephrotoxicity, Lomustine
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A patient is presented who developed nephrotoxicity after therapy with lomustine (CCNU) for astrocytoma of the brain. Only three other cases of lomustine nephrotoxicity have been reported, and all cases have been associated with cumulative drug doses of greater than 1,500 mg/m2. The clinical and pathologic features of lomustine nephrotoxicity are reviewed. It is recommended that cumulative doses of more than 1,200–1,400 mg/m2 lomustine be avoided because of the risk of nephrotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berglund J (1980) Progressive renal insufficiency after CCNU therapy. Läkartidningen 77:1760

    Google Scholar 

  2. Goupil A, Baglin A, Clavel B, Verger C, Fritel D (1980) Insuffisance rénale chronique après traitment par le CCNU. Nouv Presse Med 9:3069–3070

    Google Scholar 

  3. Oliverio VT (1973) Toxicology and pharmacology of the nitrosoureas. Cancer Chemother Rep [3] 4:13–20

    Google Scholar 

  4. Silver HKB, Morton DL (1979) CCNU nephrotoxicity following sustained remission in oat cell carcinoma. Cancer Treat Rep 63:226–227

    Google Scholar 

  5. Weiss RB, Poster DS (1982) The renal toxicity of cancer chemotherapeutic agents. Cancer Treat Rev 9:37–56

    Google Scholar 

  6. Weiss RB, Posada JG, Kramer RA, Boyd MR (1983) Nephrotoxicity of semustine. Cancer Treat Rep 67:1105–1112

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Medical Oncology, Walter Reed Army Medical Center, 20307-5001, Washington, DC, USA

    Mark E. Ellis & Raymond B. Weiss

  2. Uniformed Services University of the Health Sciences, 20814, Bethesda, MD, USA

    Mark E. Ellis & Raymond B. Weiss

  3. Hematology-Oncology Associates of Virginia, 23226, Richmond, VA, USA

    Mario Kuperminc

Authors
  1. Mark E. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond B. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario Kuperminc
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The opinions expressed are solely those of the authors and are not to be construed as reflecting the views of any U.S. Government agency

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ellis, M.E., Weiss, R.B. & Kuperminc, M. Nephrotoxicity of lomustine. Cancer Chemother. Pharmacol. 15, 174–175 (1985). https://doi.org/10.1007/BF00257532

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257532

Keywords

Search

Navigation